1448255-99-9

Upstream product

• 1448256-09-4 tert-butyl N-allyl-(4-(3’-methyl-1,2,4-oxadiazol-5'-yl)-phenyl)carbamate 
• 1448256-07-2 N-allyl-4-(3'-methyl-1,2,4-oxadiazol-5'-yl)-aniline 
• 59562-68-4 3-methyl-5-(4'-fluorophenyl)-1,2,4-oxadiazole 
• 1448256-11-8 3-(4’-(3”-methyl-1 ,2,4-oxadiazol-5-yl)-phenyl)-5-(aminomethyl)oxazolidin-2-one 
• 1448255-95-5 3-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)-5-(azidomethyl)oxazolidin-2-one 
• 1448255-93-3 3-(4'-(3-methyl-1,2,4-oxadiazol-5-yl)-phenyl)-5-(iodomethyl)-oxazolidin-2-one 

Relevant academic research and scientific papers

NOVEL 1, 2, 4-OXADIAZOL COMPOUNDS ACTIVE AGAINST GRAM-POSITIVE PATHOGENS

The present invention relates to new oxazolidinone compounds of general formula (I) having antibiotic activity even against multiresistant bacterial strains (I).

New linezolid-like 1,2,4-oxadiazolesactive against Gram-positive multiresistant pathogens

The synthesis and the in vitro antibacterial activity of novel linezolid-like oxadiazoles are reported. Replacement of the linezolid morpholine C-ring with 1,2,4-oxadiazole results in an antibacterial activity against Staphylococcus aureus both methicillin-susceptible and methicillin-resistant comparable or even superior to that of linezolid. While acetamidomethyl or thioacetoamidomethyl moieties in the C(5) sidechain are required, fluorination of the phenyl B ring exhibits a slight effect on an antibacterial activity but its presence seems to reduce the compounds cytotoxicity. Molecular modeling performed using two different approaches - FLAP and Amber software - shows that in the binding pose of the newly synthesized compounds as compared with the crystallographic pose of linezolid, the 1,2,4-oxadiazole moiety seems to perfectly mimic the function of the morpholinic ring, since the H-bond interaction with U2585 is retained.